

# REVIEW OF DECISIONS

BOARD MEETING

7-8 December 2022, Geneva, Switzerland

# Decision 1: Consent Agenda: Board Chair Reappointment

The Gavi Alliance Board:

- a) **Reappointed** José Manuel Barroso as an Unaffiliated Board member through to 31 December 2025; and
- b) **Reappointed** José Manuel Barroso as Board Chair, with individual signatory authority on behalf of the Gavi Alliance, for a second term through to 31 December 2025.

# Decision 2: Consent Agenda: Board Committee Chair Appointment

The Gavi Alliance Board:

**Appointed** Yibing Wu as Chair of the Investment Committee effective 1 January 2023 and until 31 December 2023.

# Decision 3: Consent Agenda: Board and Committee nominations (1/5)

The Gavi Alliance Board:

a) **Appointed** the following Board Members:

- **Mphu Ramatlapeng** as an Unaffiliated Board member in the seat currently held by Margaret (Peggy) Hamburg effective 1 January 2023 and until 31 December 2025.
- **Gabriella Fésüs** as Board Member representing the European Commission on the donor constituency cluster anchored by Germany in the seat currently held by Bernhard Braune of Germany, effective 1 January 2023 and until 31 December 2023.
- **Saad Omer** as Board Member representing the research & technical health institutes constituency in the seat currently held by Marta Nunes, effective 1 January 2023 and until 31 December 2023.
- **Andrew (Drew) Otoo** as Board Member representing the vaccine industry industrialised countries in the seat currently held by Roger Connor, effective 1 January 2023 and until 31 December 2025.

# Decision 3: Consent Agenda: Board and Committee nominations (2/5)

b) Reappointed the following Board Members:

- **John Arne Røttingen** as Board Member representing Norway on the donor constituency cluster anchored by Norway, effective 1 January 2023 and until 31 December 2023.

c) Appointed the following Alternate Board Members:

- **Jérémie Forrat-Jaime** as Alternate Board Member to Gabriella Fésüs representing France on the donor constituency cluster anchored by Germany in the seat currently held by Gabriella Fésüs of the European Commission, effective 1 January 2023 and until 31 December 2023.
- **Rhoda Wanyenze** as Alternate Board Member to Saad Omer representing the research & technical health institutes constituency in the seat currently held by Saad Omer, effective 1 January 2023 and until 31 December 2025.
- **Joan Benson** as Alternate Board Member to Drew Otoo representing the vaccine industry industrialised countries constituency in the seat currently held by An Vermeersch, effective 1 January 2023 and until 31 December 2025.

# Decision 3: Consent Agenda: Board and Committee nominations (3/5)

d) Reappointed the following Alternate Board Members:

- **Francesca Manno** as Alternate Board member to Takeshi Akahori representing Italy on the donor constituency cluster anchored by Japan, effective 1 January 2023 and until 31 December 2023.
- **Joris Jurriëns** as Alternate Board member to John Arne Røttingen representing the Netherlands on the donor constituency cluster anchored by Norway, effective 1 January 2023 and until 31 December 2023.

e) Reappointed the following to the Market-Sensitive Decisions Committee effective 1 January 2023:

- **José Manuel Barroso** (Board Chair) until 31 December 2023
- **Gabriella Fésüs** (Board Member) until 31 December 2023

# Decision 3: Consent Agenda: Board and Committee nominations (4/5)

- f) **Appointed** the following to the Governance Committee effective 1 January 2023:
- **Deena Shiff** (Board Member) until 31 December 2023
  - **Joan Benson** (Alternate Board Member) until 31 July 2023
  - **Jérémie Forrat-Jaime** (Alternate Board Member) until 31 December 2023
- g) **Reappointed** the following to the Governance Committee effective 1 January 2023:
- **John-Arne Røttingen** (Board Member) until 31 December 2023
- h) **Reappointed** the following to the Audit and Finance Committee effective 1 January 2023:
- **Joshua Tabah** (Alternate Board Member) until 31 December 2023

# Decision 3: Consent Agenda: Board and Committee nominations (5/5)

- i) **Appointed** the following to the Programme and Policy Committee effective 1 January 2023:
- **Beth Arthy** (Board Member) until 31 December 2023
  - **Adrien de Chaisemartin** (Committee Delegate) until 31 December 2023
  - **Hanna Nohynek** (Independent Expert) until 31 December 2023
- j) **Reappointed** the following to the Programme and Policy Committee effective 1 January 2023:
- **Bernhard Braune** (Committee Delegate) until 31 December 2023



# Decision 4: Consent Agenda: Independent Review Committee appointments

The Gavi Alliance Board:

**Appointed** as new IRC members the individuals listed in Annex A to Doc 01d, effective immediately and until 31 March 2026.

# Decision 5: Consent Agenda: Amendment to Board and Board Committee Operating Procedures

The Gavi Alliance Board:

**Amended** Section 25.1 of the Board and Board Committee Operating Procedures to read as follows:

Appointment and term: The CEO shall be selected by the Board based on merit, in a non-political, open and competitive manner. The CEO shall be appointed to renewable terms of **three** year.

# Decision 6: Consent Agenda: COVAX Facility Governance

The Gavi Alliance Board:

- a) **Dissolved** the COVAX Shareholders Council with effect on 31 December 2022;
- b) **Dissolved** the COVAX Consensus Group with effect on 31 December 2022;
- c) **Approved** the amendments to the Terms of Reference of the COVAX AMC Engagement Group as set out in Annex B to Doc 01d;
- d) **Approved** the amendments to the Market-Sensitive Decisions Committee Charter as set out in Annex C to Doc 01d; and
- e) **Extended** the term of the COVID-19 Vaccination Delivery Support Temporary Steering Committee to 30 April 2023.

# Decision 7: Consent Agenda: IFFIm CEPI Arrangement

The Gavi Alliance Board:

**Approved** an Assessment Framework exemption to allow funding for CEPI's non-COVID-19 programmes. This exemption shall be applicable only to the transactions related to a single Australian grant (not exceeding AUD 50 million) and a single Spanish grant (not exceeding EUR 75 million) intended for CEPI's support.

# Decision 8: Consent Agenda: Appointment of Independent Auditor

In accordance with the Gavi Independent Auditor Selection and Evaluation Policy, the Gavi Alliance Board:

- a) **Reappointed** Deloitte SA as the independent auditor of Gavi for the 5-year term from 2023 to 2027; and
- b) **Reappointed** Deloitte Tax LLP as external tax consultant of Gavi for the 5-year term from 2023 to 2027.

# Decision 9: Consent Agenda: Amendment of Audit and Investigations Terms of Reference

The Gavi Alliance Board:

**Approved** the amended Audit and Investigations Terms of Reference attached as Annex D to Doc 01d.

# Decision 10: Consent Agenda: Gavi support for Inactivated Poliovirus Vaccine

The Gavi Alliance Board:

**Approved** continuation of the IPV support approach approved in 2019, namely that countries are exempt from Gavi eligibility and co-financing policies until polio eradication and the withdrawal of bOPV from routine immunisation schedules.

# Decision 11: Financial update, including forecast

The Gavi Alliance Board:

- a) **Noted** that the Audit and Finance Committee reviewed the financial implications of the recommendations made by the Programme and Policy Committee and concluded that these recommendations could be approved by the Gavi Alliance Board in accordance with the Programme Funding Policy;
- b) **Approved** the updated Financial Forecast for the **Gavi 5.0** (2021-2025) Strategic Period of Qualifying Resources of US\$ 10.4 billion and Forecast Expenditure of US\$ 10.2 billion;
- c) **Approved** the updated Financial Forecast for **COVAX AMC** (2020-2023) of Qualifying resources of US\$ 12.5 billion and Forecast Expenditure of US\$ 12.5 billion (made up of US\$ 10.7 billion base expenditure and US\$ 1.8 billion pandemic vaccine pool); and
- d) **Approved** the illustrative Financial Forecast for the **Gavi 6.0** (2026–2030) Strategic Period of Qualifying Resources of US\$ 8.8 billion and Forecast Expenditure of US\$ 8.5 billion, noting that only **existing programmes have been forecast** and the forecast has been prepared to enable the Secretariat to allot funding to these programmes in accordance with the Programme Funding Policy and **does not prejudge future donor contributions or future investment decisions**.



# Decision 12: Partners' Engagement Framework and Secretariat Budget (2023-2024)

The Gavi Alliance Board:

- a) **Approved**, US\$ 149.8 million in 2023 and US\$ 152.8 million in 2024 for Secretariat Resources excluding COVAX.
- b) **Approved**, US\$ 1.0 million in 2023 and US\$ 1.0 million in 2024 for capital expenditure budgets.
- c) **Approved** the COVAX Operating budget of US\$ 43 million in 2023.
- d) **Approved** the Gavi 5.1 Operating budget for the additional targeted priorities related to the pandemic of US\$ 27.7 million in 2024 noting these additional priorities are subject to Board approval of the Gavi 5.1 strategy and contingent on funding being made available.
- e) **Approved** US\$ 73.9 million in 2023 and US\$ 73.1 million in 2024 for the Partners' Engagement Framework budget including:
  - i. US\$ 5.2 million in 2023 for COVAX procurement fees;
  - ii. Continuation of US\$ 2 million complexity fee relating to UNICEF procurement of Gavi 5.0 vaccines during the pandemic for both 2023 and 2024;
  - iii. US\$ 2.4 million in 2024 for procurement fees for the additional targeted priorities related to the pandemic.
- f) **Requested** that the Secretariat prepare a report on Secretariat workforce planning, including COVAX integration, for Governance Committee and Audit and Finance Committee review during Q2 2023.

# Decision 13: Risk and Assurance Report

The Gavi Alliance Board:

**Approved** the Risk & Assurance Report 2022 attached as Annex A to Doc 05.

# Decision 14: Gavi 5.1

The Gavi Alliance Board:

**Approved** the updated framework for Gavi 5.1 (updated 'strategy one-pager') attached as Annex A to Doc 06.

# Decision 15: Human papillomavirus (HPV) Vaccine Programme relaunch

The Gavi Alliance Board:

- a) **Approved** the four strategic shifts for the HPV programme relaunch, which are:
1. To facilitate and accelerate adoption of a permissive 1-dose schedule and support recovery of original and missed cohorts up to 18 years of age for countries with delayed multi-age cohort (MAC) vaccinations;
  2. Optimise and increase the relevant HSS investments/mechanisms that support accelerating and strengthening of the HPV programme;
  3. Enhanced technical assistance through Technical Country Assistance (TCA) and Foundational Support (FS);
  4. Learning agenda support through Strategic Focus Area (SFA) for integration of the HPV vaccination programme in routine immunisation delivery mechanisms and Primary Health Care (PHC).
- b) **Noted** that the HPV vaccine has amongst the highest impact of all Gavi-supported vaccines and **requested** that the Secretariat update the Programme and Policy Committee twice annually on implementation progress and return to the Board should further funding or flexibilities be needed to deliver on the ambitious relaunch agenda.

# Decision 16: Gavi's role in support to Regional and African Vaccine Manufacturing

The Gavi Alliance Board:

- a) **Approved** the first three pillars of the new approach, namely 1) support for antigen and product portfolio planning; 2) adaptation of the Healthy Market Framework and Product Menu Criteria to facilitate listing and adoption of new regional products; and 3) providing investors in new manufacturing capacity with more predictability around eventual demand; and
- b) **Requested** that the Secretariat work up detailed proposals for the design and operationalisation of Pillar 4: an Advance Market Commitment to accelerate the expansion of end-to-end African vaccine manufacturing, with three underlying objectives: (i) support healthy global markets, (ii) drive efficient market outcomes, (iii) reduce barriers to investment, noting that detailed parameters will return to the Gavi Alliance Board for consideration and approval in 2023.

# Decision 17: Gavi's role in a future COVID-19 Vaccine Programme (1/3)

The Gavi Alliance Board:

- a) **Approved**, in principle, a new programme for COVID-19 vaccination to be implemented in 2024-2025, contingent on:
- a. Continuation of the WHO base-case scenario for the pandemic evolution requiring continued focus on the higher priority user groups as per SAGE recommendation;
  - b. Consistent with the Vaccine Investment Strategy (VIS) approach, an evaluation of the COVID-19 programme based on the following criteria for assessing vaccines for epidemic disease preparedness and response:
    - i. Disease risk and burden
    - ii. Vaccine impact and feasibility
    - iii. Fit for the Gavi Alliance
    - iv. Financial implications
  - c. PPC recommendation in May 2023 to prioritise and structure this programme with regards to country scope and extent of support;
  - d. Sufficient funding as confirmed by the AFC and the Board by June 2023
  - e. Updated country demand estimates informing volume requirements; and
  - f. Further information from country experience and use of COVID-19 Delivery Support (CDS) to date.

# Decision 17: Gavi's role in a future COVID-19 Vaccine Programme (2/3)

- b) **Approved**, in principle, the following country scope and extent of support for the COVID-19 programme:
- a. Country scope: AMC91 (Gavi54 and AMC37)
  - b. Extent of support:
    - i. Gavi54: Eligible for full vaccine procurement support without co-financing obligations and delivery support (consisting of the provision of 70% of estimated total delivery costs for the vaccines).
    - ii. AMC37: Eligible for vaccine catalytic financing in line with the MICs Approach for vaccine procurement and not eligible for delivery support.
- c) **Acknowledged** that planning for a COVID-19 programme including engagement with countries would commence prior to funding commitments coming for approval by June 2023 to ensure the feasibility of a timely launch by 2024.
- d) **Noted** that any consideration of a potential COVID-19 programme beyond 2025 be integrated into the 2024 Vaccine Investment Strategy process.
- e) **Noted** that the Secretariat in early 2023 will present to the COVAX Investors Group options for the use of the COVAX AMC financing envelope for purposes relevant to preparedness and response as well as potential repurposing of funds.

# Decision 17: Gavi's role in a future COVID-19 Vaccine Programme (3/3)

The Gavi Alliance Board:

- a) **Noted** that the Secretariat will update programme assumptions and the approach for the COVID-19 programme, incorporating the latest demand estimates and the latest information on delivery, as informed by the implementation of CDS3;
- b) **Noted** that the Secretariat will return to the Board by June 2023 for approval of the final programme design and the financial envelope for 2024-2025;
- c) **Noted** that the Secretariat will update the Board at each meeting and will return to the Board formally, through the PPC, if future SAGE guidance evolves such that this programme is no longer aligned with technical guidance and/or assumptions outlined in Annex C to Doc 10 vary significantly as to affect the implementation feasibility of the programme; and
- d) **Noted** that the Secretariat will return to the Board as part of the Gavi 6.0 strategy development with proposed updates to the COVID-19 vaccination programme to account for changes in disease epidemiology as well as consideration of Gavi 6.0 priorities.



# Decision 18: Funding Policy Review

The Gavi Alliance Board:

**Approved** the Health Systems and Immunisation Strengthening Policy attached as Annex B to Doc 11a.

# Decision 19: Funding Policy Review

The Gavi Alliance Board:

- a) **Approved** the revised Eligibility & Transition Policy attached as Annex A to Doc 11b.
- b) **Approved** the revised Co-financing Policy attached as Annex B to Doc 11b.
- c) **Approved** the exceptional time-limited approach to malaria vaccine co-financing as follows, to be reviewed by the Programme and Policy Committee no later than 2027:
  - i. For initial self-financing countries: Country contributes US \$0.20 per dose (no annual increase).
  - ii. For preparatory transition countries: Country co-financing starts at US \$0.20 per dose in the first year of introduction and the price fraction increases by 15% annually.
  - iii. For accelerated transition countries: Country contributes 20% of the price fraction in the first year of introduction and increases co-financing by 10 percentage points annually. Country should reach 100% co-financing after 8 years.
- d) **Noted** that the Secretariat will return to the Programme and Policy Committee on malaria co-financing should market conditions change significantly.
- e) **Requested** that the Secretariat reports regularly to the Board on the Alliance support for transition preparation, on progress of individual countries in Accelerated Transition, and potential risks of unsuccessful transition.

# Thank you